TNXP โ€“ Tonix Pharmaceuticals โ€“ 30-Min Long Trade Setup !

132
๐Ÿ“ˆ ๐Ÿš€
๐Ÿ”น Asset: TNXP (NASDAQ)
๐Ÿ”น Timeframe: 30-Min Chart
๐Ÿ”น Setup Type: Symmetrical Triangle Breakout + Trendline Support

๐Ÿ“Š Trade Plan (Long Position)
โœ… Entry Zone: Above $26.53 (Breakout zone + trendline support)
โœ… Stop-Loss (SL): Below $23.81 (Previous support & trendline base)

๐ŸŽฏ Take Profit Targets
๐Ÿ“Œ TP1: $31.64 (Previous resistance zone)
๐Ÿ“Œ TP2: $37.76 (Major resistance / measured move target)

๐Ÿ“Š Risk-Reward Ratio Calculation
๐Ÿ“‰ Risk (SL Distance):
$26.53 - $23.81 = $2.72 risk per share

๐Ÿ“ˆ Reward to TP1:
$31.64 - $26.53 = $5.11 โ†’ (1.88:1 R/R)
๐Ÿ“ˆ Reward to TP2:
$37.76 - $26.53 = $11.23 โ†’ (4.13:1 R/R)

๐Ÿ” Technical Analysis & Strategy
๐Ÿ“Œ Triangle Breakout: Price consolidating and now testing triangle resistance
๐Ÿ“Œ Volume Pick-up Expected: Ideal breakout candidate if volume expands above $26.53
๐Ÿ“Œ Trendline Support Holding: Consistent higher lows with bullish structure
๐Ÿ“Œ Break + Retest Zone: Yellow zone acting as breakout confirmation

โš™๏ธ Trade Execution & Risk Management
๐Ÿ“Š Wait for a 30-min bullish close above $26.53
๐Ÿ“‰ Trailing Stop Strategy:
Move SL to breakeven after hitting TP1

๐Ÿ’ฐ Partial Profit Booking Strategy
โœ” Book 50% at TP1 = $31.64
โœ” Let the rest ride toward TP2 = $37.76
โœ” Trail SL above entry to secure gains

โš ๏ธ Breakout Failure Risk
โŒ Setup invalid if price breaks below $23.81
โŒ Avoid entry without clear breakout close above $26.53

๐Ÿš€ Final Thoughts
โœ” Triangle breakout + trendline support = solid bullish setup
โœ” Reward potential up to 4.13:1 R/R
โœ” Clean structure, strong confluence, manageable risk

๐Ÿ”— #TNXP #NASDAQ #BreakoutTrade #SwingTrading #ProfittoPath #TechnicalSetup #TriangleBreakout #TrendlineSupport #StockTrading #RiskReward #PharmaStocks

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.